MindMaze Therapeutics Holding (CHIX:MMTXZ) Valuation Rank


CHIX:MMTXZ MindMaze Therapeutics Holding SA CHIX:MMTXZ
15 GF Score
Price CHF0.21
! 2 Warning Signs
View Full Analysis

What is MindMaze Therapeutics Holding Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

MindMaze Therapeutics Holding Valuation Rank Related Terms

CHIX:MMTXZ
15GF Score
MindMaze Therapeutics Holding SA CHIX:MMTXZ
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MindMaze Therapeutics Holding Business Description

Other Exchanges RLFTY:USAMMTX:Switzerland
Address Avenue de Secheron 15, Geneva, CHE, 1202
MindMaze Therapeutics Holding SA is a Swiss-based, commercial-stage biopharmaceutical and neurotechnology company. The company develops and commercializes digital treatments for neurological diseases and brain disorders. Its technology platform integrates software, sensors, and telehealth, and its solutions are used in clinical and home settings internationally. The company has developed evidence-based, next-generation neurotherapeutics that provide evidence-based motor and cognitive treatments to redefine clinical outcomes in patients with neurological disease and brain disorders. The company also manages Relief's existing portfolio of clinical and commercial biopharmaceutical assets focused on rare dermatological, metabolic, and respiratory diseases.
15GF Score

Get the complete analysis for CHIX:MMTXZ

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF0.21
Price